These protocols are currently being employed in an ongoing co-clinical trial to assess the effects of neoadjuvant and adjuvant programmed cell death protein 1 (PD-1) inhibition in sarcomas treated with neoadjuvant radiation therapy and surgical resection [19] (see Fig 1). Here, PDCD1 is linked to sarcoma.